These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12060153)

  • 81. PET as a potential tool for imaging molecular mechanisms of oncology in man.
    Price P
    Trends Mol Med; 2001 Oct; 7(10):442-6. PubMed ID: 11597518
    [TBL] [Abstract][Full Text] [Related]  

  • 82. PET in oncology II--other tumours.
    Nunan TO; Hain SF
    Nucl Med Commun; 2000 Mar; 21(3):229-33. PubMed ID: 10823323
    [No Abstract]   [Full Text] [Related]  

  • 83. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders.
    Basu S; Kwee TC; Gatenby R; Saboury B; Torigian DA; Alavi A
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):987-91. PubMed ID: 21451997
    [No Abstract]   [Full Text] [Related]  

  • 84. [PET in oncology].
    Lomeña F; Gámez C; Cabrera A; Maldonado A; Jiménez A
    Rev Esp Med Nucl; 2000 Dec; 19(7):510-24, quiz 525-7, 532. PubMed ID: 11171512
    [No Abstract]   [Full Text] [Related]  

  • 85. Positron emission tomography for tumour assessment.
    Jones T; Tilsley DW; Wilson CB; Lammertsma AA; Brown G; Brady F; Price PM
    NMR Biomed; 1992; 5(5):265-9. PubMed ID: 1449966
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pat Price discusses the potential of molecular imaging for drug development. Interview by Joanna Owens.
    Price P
    Drug Discov Today; 2003 Mar; 8(5):196-8. PubMed ID: 12634008
    [No Abstract]   [Full Text] [Related]  

  • 87. [Positron emission tomography--PET].
    Lind P
    Wien Med Wochenschr; 2002; 152(11-12):254. PubMed ID: 12138650
    [No Abstract]   [Full Text] [Related]  

  • 88. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma.
    Wang HY; Ding HJ; Chen JH; Chao CH; Lu YY; Lin WY; Kao CH
    Cancer Imaging; 2012 Oct; 12(3):464-74. PubMed ID: 23108238
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical applications of FDG-PET in oncology.
    Czernin J
    Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
    Giorgetti A; Volterrani D; Mariani G
    Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Current status of positron emission tomography in oncology.
    Scott AM
    Australas Radiol; 2002 Jun; 46(2):154-62. PubMed ID: 12060153
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Current status of positron emission tomography in oncology.
    Scott AM
    Intern Med J; 2001; 31(1):27-36. PubMed ID: 11478353
    [TBL] [Abstract][Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.